Upper Respiratory Infections Clinical Trial
Official title:
An Open Label, In-use Study to Assess the Warming Sensation, Acceptability and Local Tolerability of Paracetamol 500 mg + Pseudoephedrine 30 mg Syrup Given as a 30 ml Single Dose in Subjects Suffering From Symptoms of an Upper Respiratory Tract Infection
Verified date | April 2013 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
This is an open label, in-use study to assess the warming sensation, acceptability and local
tolerability of paracetamol 500 mg + pseudoephedrine 30 mg syrup, given as a single dose in
subjects suffering from symptoms of an upper respiratory tract infection. The purpose is to
evaluate the acceptability concerning a warming sensation effect and its potential benefit
in the target population.
The primary objective is to assess the warming sensation caused by the excipient IFF flavor
316 282, in a syrup containing paracetamol 500 mg + pseudoephedrine 30 mg per 30 ml syrup.
The syrup contains (0.15% w/v) warming flavor.
The Secondary Objectives are to assess subject acceptability of the syrup and the safety and
tolerability of the syrup. The study will be run in fifty-six (56) subjects suffering from
symptoms of an upper respiratory tract infection (URTI) for 7 days or less, e.g. nasal
congestion associated with colds and flu symptoms such as pain, headache and/or fever.
Subjects must have one or more symptoms per category:
1. mild to moderate body pain, headache, fever or sore throat
2. nasal congestion (blocked nose) with or without rhinorrhea (runny nose) or sneezing
Adolescents will be included in the study population
Status | Completed |
Enrollment | 56 |
Est. completion date | May 2012 |
Est. primary completion date | May 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Years and older |
Eligibility |
Inclusion Criteria: - Subject must have one or more symptoms per category (see also screening assessment of cold symptoms, section 6.1): - mild to moderate body pain, headache, fever or sore throat - nasal congestion (blocked nose) with or without rhinorrhea (runny nose) or sneezing Exclusion Criteria: 1. Baseline sore throat pain of severe intensity, e.g. rated as 3 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe) 2. Baseline dry cough of severe intensity, e.g. rated as 3 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe) 3. Subject has a productive cough. 4. History of hypersensitivity to any of the study drugs and the listed excipients or to drugs of similar chemical classes 5. Subjects with allergic asthma. 6. Use of any inhaler, medicated confectionary, throat lozenges, throat pastilles, sprays, any products with demulcent properties such as chewing gums and boiled sweets or mints, in the 6 hours prior to dosing. 7. Use of any medication for sore throat containing a local anaesthetic within the 6 hours prior to dosing. 8. Use of paracetamol, any NSAID or any oral nasal decongestant within 6 hours prior to dosing. 9. Use of substances of abuse or antihistamines within 24 hours of dosing. 10. Drinking of tea, coffee or other caffeinated beverages 1 hour prior to dosing. 11. Suffering from hepatic or severe renal impairment, hypertension, hyperthyroidism, diabetes, heart disease or other acute or chronic medical condition that, in the opinion of the investigator, would put the subject at a higher risk or affect the conduct and/or the results of the study. 12. Use of any antidepressants, monoamine oxidase inhibitors or beta-blocking drugs in the 28 days prior to dosing 13. A history of alcohol abuse or subject admits to regular consumption of alcohol in excess of the recommended weekly limits of 21 units for females and 28 units for males. 14. Subject is a current smoker of =10 cigarettes per day (or reports equivalent smoking habits using other tobacco products). 15. Subject has smoked or chewed tobacco products within 12 hours of dosing. 16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. |
Intervention Model: Single Group Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
Canada | Algorithme Pharma | Montreal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Novartis | Novartis Consumer Health |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Pseudoephedrine 30 mg Per 30 ml Syrup | Intensity of warming sensation felt by subjects between predose to 1 minute postdose where 0 = no warming sensation and 100 = strongest possible warming sensation | 1 minute | No |
Secondary | Subject Acceptability of the Syrup | How do you like the warming sensation you have experienced for this product? Possible responses are : Like extremely Like very much Like moderately Like slightly Neither like nor dislike Dislike slightly Dislike moderately Dislike very much Dislike extremely |
1 hour | No |
Secondary | Safety and Tolerability of the Syrup | Number of participants with adverse events. | 1 hour | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02451163 -
DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly
|
Phase 2 | |
Recruiting |
NCT01971112 -
Nutritional Intervention and Respiratory Infections in Older Subjects
|
N/A | |
Completed |
NCT01717534 -
Children Immune Functions
|
N/A | |
Completed |
NCT01728090 -
Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections
|
Phase 4 | |
Completed |
NCT00235703 -
Inter-Mountain Project on Antimicrobial Resistance and Therapy (IMPART)
|
N/A | |
Completed |
NCT02232711 -
Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting
|
N/A | |
Completed |
NCT01731392 -
Children Immune Functions(2)
|
N/A | |
Withdrawn |
NCT00773435 -
Effects of Echinacea in Children
|
N/A | |
Completed |
NCT03464279 -
Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections
|
N/A | |
Completed |
NCT01576809 -
Warming Sensation Intensity and Acceptability of the Flavour, Local Tolerability of Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Syrup in Patients Suffering a Upper Respiratory Tract Infection (URTI)
|
Phase 3 | |
Completed |
NCT00611195 -
Remifentanil and Laryngeal Reflex Responses in Pediatric Patients With URI
|
Phase 4 | |
Completed |
NCT02225912 -
A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers
|
Phase 4 |